News | May 25, 2023
JB Pharma records revenue growth of 22% to Rs. 762 Cr
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
This product is based on Osmotic Controlled Release Oral Delivery System technology
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
Health resources – both human and material are precious assets to the society and a robust health care administration and management system ensures their effective utilization: Dr Bharati Pravin Pawar
The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores
Subscribe To Our Newsletter & Stay Updated
